Using the sleep-disorder drug Provigil as a case study, this article exposes a new type of anticompetitive harm that stems from the combination of two distinct activities. First, brand-name drug firms such as Cephalon, the developer of Provigil, have settled patent litigation by paying generic … Read more
Author: Michael Carrier
The Hastings Science & Technology Law Journal (STLJ) is a multidisciplinary journal created to enrich the discourse at the nexus of science, scientific methodology, technology, biotechnology, bioethics, health, public policy, and the law. STLJ is designed to serve both the legal and scientific communities through prompt publication of scholarly works on the basis of originality, insight, timeliness, and elegance, and by providing an open forum for the discussion and interpretation of significant developments in science and law.